Symbiotec Pharmalab IPO 2026: Price Band, GMP, Subscription, Financials & Key Details

The Symbiotec Pharmalab IPO is scheduled to open for subscription on August 24, 2026, and close on August 27, 2026. The IPO is a ₹1,757 crore Mainboard Book Build Issue, comprising a fresh issue of ₹150 crore and an Offer for Sale (OFS) of ₹1,607 crore.

The IPO price band has been fixed at ₹938 to ₹988 per share, with a face value of ₹2 per equity share. Retail investors can apply for a minimum of 15 shares, requiring an investment of ₹14,820 at the upper price band.

The shares are proposed to be listed on both the NSE and BSE on September 1, 2026.

Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products. The company has a strong presence in steroidal and corticosteroid APIs and caters to both domestic and international markets.

In this article, we cover the Symbiotec Pharmalab IPO details, GMP, IPO timeline, lot size, subscription status, reservation, financial performance, business model, IPO objectives, strengths, risks, peer comparison, allotment and key investor considerations.

Symbiotec Pharmalab IPO Details

Symbiotec Pharmalab IPO Timeline

All dates are tentative and subject to change.

Symbiotec Pharmalab IPO GMP

As of August 19, 2026, the Symbiotec Pharmalab IPO GMP is ₹0.
 

At a GMP of ₹0, the estimated listing price is around ₹988 per share, which is equal to the upper end of the IPO price band.
GMP is an unofficial market indicator and can change before listing. Investors should not rely solely on GMP when evaluating an IPO.

Symbiotec Pharmalab IPO Subscription Status

The Symbiotec Pharmalab IPO will open for subscription on August 24, 2026 and close on August 27, 2026.
The live subscription data is currently unavailable as bidding has not started.
 

The subscription figures will be updated once bidding begins.

Symbiotec Pharmalab IPO Day-wise Subscription Trend

What is the Current Subscription Data for Symbiotec Pharmalab?

The live subscription data for the Symbiotec Pharmalab IPO is currently unavailable because the IPO has not opened for bidding.

Once the issue opens, subscription figures will be updated based on bids received from QIB, NII and Retail investors.

Symbiotec Pharmalab IPO Reservation

What is Symbiotec Pharmalab Ltd.?

Incorporated in 2002, Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients and specialty products.

The company caters to customers across domestic and international markets, including regulated and emerging markets. Its operations focus on research-driven manufacturing, quality compliance and sustainable production processes.

Symbiotec has evolved from a lab-scale steroidal-hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform.

The company has approvals and certifications from regulatory organisations including the US FDA, EU-GMP and Ministry of Food and Drug Safety, Korea, among others.

As of June 30, 2025, Symbiotec had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.

Competitive Strengths

• Global leadership in corticosteroid and steroidal-hormone APIs
• Long-standing relationships with domestic and international customers
• Vertically integrated and backward-integrated manufacturing platform
• Strong regulatory and compliance track record
• Continuous investment in research and development
• Ability to expand its addressable market through technology and existing capabilities

Symbiotec Pharmalab IPO Objectives

The company proposes to utilise the net proceeds from the fresh issue towards repayment of outstanding borrowings and general corporate purposes.
 

A significant portion of the fresh issue proceeds is therefore intended to strengthen the company's balance sheet by reducing outstanding debt.

Symbiotec Pharmalab Financial Performance

Symbiotec Pharmalab has reported growth in revenue and profitability during FY26.

The company's total income increased from ₹723.33 crore in FY24 to ₹872.26 crore in FY26. PAT stood at ₹109.90 crore in FY26, compared with ₹96.79 crore in FY25.
The company also reduced its total borrowings from ₹540.92 crore in FY25 to ₹387.91 crore in FY26.

Symbiotec Pharmalab Key Financial Ratios

The company has maintained healthy profitability and EBITDA margins, although ROE, RoNW and operating margins declined slightly compared with FY25.

Symbiotec Pharmalab IPO Valuation

Based on the provided IPO financial data:
 

At the upper price band of ₹988, the company is being valued at a relatively high earnings multiple. Investors should compare this valuation with the company's growth rate, profitability, return ratios and listed pharmaceutical peers.

Symbiotec Pharmalab IPO Peer Comparison

The company's peer comparison based on DRHP/RHP data is as follows:

Peer financial metrics are based on the data provided in the company's DRHP/RHP.

Competitive Strengths of Symbiotec Pharmalab

Strong Position in Steroidal APIs

Symbiotec has established capabilities in corticosteroid and steroidal-hormone APIs, which form an important part of its pharmaceutical manufacturing business.

Backward-Integrated Manufacturing

The company's vertically integrated manufacturing platform provides greater control over its production processes and supply chain.

Global Regulatory Approvals

Approvals and certifications from international regulatory bodies support the company's ability to serve customers across regulated markets.

Established Customer Relationships

The company has developed long-term relationships with domestic and international pharmaceutical customers.

Research and Development Capabilities

Symbiotec continues to invest in R&D and technology to expand its product portfolio and addressable market.

Risks Investors Should Consider

Dependence on Pharmaceutical Industry

The company's revenue is dependent on demand from pharmaceutical, nutraceutical and related industries.

Regulatory Risks

Pharmaceutical manufacturing is subject to stringent regulatory requirements. Any regulatory issues could affect production, exports and business operations.

Customer Concentration

Dependence on major customers can create business risks if relationships are discontinued or order volumes decline.

Raw Material and Manufacturing Risks

Changes in the cost and availability of raw materials can affect margins and profitability.

High IPO Valuation

The IPO valuation needs to be assessed carefully against the company's earnings growth and return ratios.

Competition

The company operates in a competitive pharmaceutical and API manufacturing market with several established domestic and international players.

Should You Invest in Symbiotec Pharmalab IPO?

Symbiotec Pharmalab provides investors exposure to India's API and pharmaceutical manufacturing sector, particularly the steroidal and corticosteroid API segment.

The company has an established operating history, international regulatory approvals, vertically integrated manufacturing capabilities and a diversified customer base. Its FY26 total income stood at ₹872.26 crore, while PAT increased to ₹109.90 crore.

The company has also reduced borrowings compared with FY25, while the IPO proceeds are partly intended for repayment of outstanding debt.

However, investors should consider the company's valuation, declining return ratios, regulatory exposure, competitive environment and dependence on pharmaceutical demand before making an investment decision.

The current GMP of ₹0 indicates no unofficial premium over the upper issue price as of August 19, 2026. GMP can change before listing and should not be treated as a guaranteed indicator of listing performance.

Symbiotec Pharmalab IPO Allotment Status

The allotment of shares for the Symbiotec Pharmalab IPO is expected to be finalized on August 28, 2026.
Applicants can check their IPO allotment status after it is declared through the official registrar, MUFG Intime India Pvt. Ltd.

How to Check Symbiotec Pharmalab IPO Allotment Status?

• Visit the MUFG Intime IPO allotment page.
• Select Symbiotec Pharmalab from the issuer list.
• Choose PAN, application number or DP ID/client ID.
• Enter the required details.
• Click on the search option.
• The allotment status will be displayed on the screen.
• Investors can also receive allotment and refund updates through their registered bank, broker, email or SMS.

Symbiotec Pharmalab IPO Registrar

1. Registrar: MUFG Intime India Pvt. Ltd.
2. Website: MUFG Intime India – Initial Public Offer
3. Phone: 022-49186000
4. Email: symbiotecpharmalab.ipo@in.mpms.mufg.com

The registrar is responsible for processing IPO applications, finalizing the basis of allotment, crediting shares to successful applicants and processing refunds.

Symbiotec Pharmalab IPO Lead Managers

The book-running lead managers for the IPO are:

• JM Financial Ltd.
• Motilal Oswal Investment Advisors Ltd.
• Nomura Financial Advisory & Securities (India) Pvt. Ltd.
• Avendus Capital Pvt. Ltd.

Symbiotec Pharmalab Company Details

Registered Office:
Symbiotec Pharmalab Ltd.
385/2, Pigdamber, Rau,
Mhow, Indore,
Madhya Pradesh – 453331
Website: Symbiotec Pharmalab
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com

Summary

The Symbiotec Pharmalab IPO is a ₹1,757 crore Mainboard Book Build Issue, comprising a ₹150 crore fresh issue and ₹1,607 crore OFS. The IPO price band is fixed at ₹938–₹988 per share, with a minimum retail investment of ₹14,820.

The company operates in the pharmaceutical and biotechnology sector, with a strong focus on APIs, corticosteroid and steroidal-hormone ingredients, nutritional ingredients and specialty products.

Symbiotec reported ₹872.26 crore total income and ₹109.90 crore PAT in FY26. Its borrowings also declined from ₹540.92 crore in FY25 to ₹387.91 crore in FY26.

At present, the GMP is ₹0, indicating no unofficial premium over the upper issue price. Investors should evaluate the company's financial performance, valuation, industry outlook, competitive position and risks before investing.

Frequently Asked Questions (FAQs)

What is the Symbiotec Pharmalab IPO?

Symbiotec Pharmalab IPO is a ₹1,757 crore Mainboard Book Build IPO, consisting of a ₹150 crore fresh issue and ₹1,607 crore Offer for Sale.

What are the Symbiotec Pharmalab IPO dates?

The IPO will open on August 24, 2026, and close on August 27, 2026.

What is the Symbiotec Pharmalab IPO price band?

The price band is fixed at ₹938 to ₹988 per share.

What is the lot size of Symbiotec Pharmalab IPO?

The minimum IPO lot size is 15 shares. At the upper price band of ₹988, the minimum investment is ₹14,820.

What is the Symbiotec Pharmalab IPO GMP today?

As of August 19, 2026, the Symbiotec Pharmalab IPO GMP is ₹0.

When will Symbiotec Pharmalab IPO allotment take place?

The tentative IPO allotment date is August 28, 2026.

When will Symbiotec Pharmalab IPO list?

The shares are expected to list on September 1, 2026, on both NSE and BSE.

What is the total issue size of Symbiotec Pharmalab IPO?

The total IPO size is ₹1,757 crore, consisting of a ₹150 crore fresh issue and ₹1,607 crore OFS.

What does Symbiotec Pharmalab do?

Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in manufacturing APIs, nutritional ingredients and specialty products, with a strong focus on steroidal and corticosteroid APIs.

What is the minimum investment required for the IPO?

Retail investors need to apply for at least 15 shares, requiring ₹14,820 at the upper price band of ₹988 per share.

Disclaimer

This article is intended for informational and educational purposes only and should not be considered financial or investment advice. IPO details, Grey Market Premium (GMP), subscription figures, allotment dates and listing timelines are subject to change. Investors should carefully read the Red Herring Prospectus (RHP), verify the latest information from official sources and consult a qualified financial advisor before making any investment decision. Investments in the stock market are subject to market risks.

Author: Komal Bhatt

Komal Bhatt is a finance content writer at InvestKraft, specialising in well-researched articles on financial products, stock markets, and investment opportunities, with a particular focus on unlisted shares.

She holds a Master’s degree in Commerce from the University of Delhi, which gives her a solid academic foundation in finance and business. With over three years of hands-on experience in creating digital finance content, Komal has developed a clear understanding of investor needs through her work on wealth management, NISM certification programs, and market education materials.

Komal is passionate when it comes to breaking down complex financial concepts into simple, accurate and actionable insights. Her goal is to help everyday investors understand markets better and make more informed decisions based on reliable, research-backed information.